Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Sells 2,401 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet sold 2,401 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $581.00, for a total transaction of $1,394,981.00. Following the sale, the executive vice president now directly owns 353 shares of the company’s stock, valued at approximately $205,093. This trade represents a 87.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Myriam Curet also recently made the following trade(s):

• On Tuesday, February 11th, Myriam Curet sold 408 shares of Intuitive Surgical stock. The shares were sold at an average price of $589.75, for a total transaction of $240,618.00.

Intuitive Surgical Trading Down 3.0 %

ISRG traded down $17.16 during trading on Thursday, reaching $563.77. 1,479,693 shares of the company were exchanged, compared to its average volume of 1,715,986. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00. The firm has a 50 day moving average of $568.10 and a 200 day moving average of $527.65. The stock has a market cap of $200.80 billion, a P/E ratio of 87.95, a PEG ratio of 5.85 and a beta of 1.39.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. CICC Research started coverage on Intuitive Surgical in a research note on Monday, January 27th. They issued a “neutral” rating and a $550.00 price target on the stock. Bernstein Bank raised their price objective on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. UBS Group upped their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, Piper Sandler reissued an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Hedge Funds Weigh In On Intuitive Surgical

Several institutional investors have recently modified their holdings of the company. Norges Bank acquired a new position in Intuitive Surgical during the 4th quarter valued at about $2,401,493,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Intuitive Surgical during the third quarter valued at approximately $558,807,000. Proficio Capital Partners LLC boosted its position in shares of Intuitive Surgical by 89,098.8% during the fourth quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock worth $495,845,000 after buying an additional 948,902 shares during the period. FMR LLC grew its holdings in Intuitive Surgical by 8.3% in the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after buying an additional 838,793 shares in the last quarter. Finally, Capital Research Global Investors increased its position in Intuitive Surgical by 25.5% in the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock valued at $1,764,904,000 after acquiring an additional 687,906 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.